89Zr-TLX250 for PET/CT Imaging of ccRCC- ZIRCON Study
NCT03849118
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
300
Enrollment
INDUSTRY
Sponsor class
Conditions
Clear Cell Renal Cell Carcinoma
Interventions
DIAGNOSTIC_TEST:
89Zr-girentuximab
Sponsor
Telix Pharmaceuticals (Innovations) Pty Limited